Netris collaborates with Orano and CLB to develop antibody-radio conjugates for cancer

Sep. 20, 2022

Netris Pharma SAS has entered into a scientific collaboration agreement with Orano SA and the Centre Léon Bérard (CLB) to develop novel antibody-radio conjugates for the treatment of cancer.

BioWorld Science Collaboration Cancer Immuno-oncology

Today's news in brief

BioWorld

BioWorld briefs for Sept. 18, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for September 17, 2024.

Big pharma eyes China ‘at forefront of GLP-1 revolution’

BioWorld

Two leading glucagon-like peptide-1 (GLP-1) receptor agonists for obesity and type 2 diabetes – Novo Nordisk A/S’s semaglutide (Wegovy/Ozempic) and Eli Lilly and...

Novo Nordisk seeks to repurpose GLP-1s, again, for the brain

BioWorld

As Novo Nordisk A/S and Eli Lilly and Co. go head-to-head in the U.S. and Chinese glucagon-like peptide-1 receptor agonists (GLP-1RA) market for diabetes and...

Partial epigenetic reprogramming to treat ischemic optic neuropathy

BioWorld

A novel gene therapy that leads to cellular rejuvenation could restore vision after non-arteritic anterior ischemic optic neuropathy (NAION) and glaucoma. The...

Upgrade your daily dose of biopharma and medtech news

Netris collaborates with Orano and CLB to develop antibody-radio conjugates for cancer